Amgen announces $13.4bn acquisition of Celgene psoriasis treatment
27-08-2019
Sundry Photography / Shutterstock.com
Amgen is unlikely to succeed in its bid to revive its patents for the cholesterol drug Repatha, a judge at the US Court of Appeals for the Federal Circuit has told the pharmaceutical company.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Amgen, cholesterol, patents, Federal Circuit, Repatha, US District Court for the District of Delaware, big pharma, Sanofi, Regeneron, anitbodies, invention
